230 related articles for article (PubMed ID: 19158152)
1. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE.
Mebazaa A; Nieminen MS; Filippatos GS; Cleland JG; Salon JE; Thakkar R; Padley RJ; Huang B; Cohen-Solal A
Eur J Heart Fail; 2009 Mar; 11(3):304-11. PubMed ID: 19158152
[TBL] [Abstract][Full Text] [Related]
2. Intravenous levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers.
Bergh CH; Andersson B; Dahlström U; Forfang K; Kivikko M; Sarapohja T; Ullman B; Wikström G
Eur J Heart Fail; 2010 Apr; 12(4):404-10. PubMed ID: 20335355
[TBL] [Abstract][Full Text] [Related]
3. Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.
Duygu H; Turk U; Ozdogan O; Akyuz S; Kirilmaz B; Alioglu E; Gunduz R; Bozkaya YT; Turkoglu C; Payzin S
Cardiovasc Ther; 2008; 26(3):182-8. PubMed ID: 18786088
[TBL] [Abstract][Full Text] [Related]
4. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial.
Mebazaa A; Nieminen MS; Packer M; Cohen-Solal A; Kleber FX; Pocock SJ; Thakkar R; Padley RJ; Põder P; Kivikko M;
JAMA; 2007 May; 297(17):1883-91. PubMed ID: 17473298
[TBL] [Abstract][Full Text] [Related]
5. Effects of levosimendan versus dobutamine on left atrial function in decompensated heart failure.
Duman D; Palit F; Simsek E; Bilgehan K; Sacide A
Can J Cardiol; 2009 Oct; 25(10):e353-6. PubMed ID: 19812809
[TBL] [Abstract][Full Text] [Related]
6. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
Follath F
Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
[TBL] [Abstract][Full Text] [Related]
7. Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients.
Kivikko M; Pollesello P; Tarvasmäki T; Sarapohja T; Nieminen MS; Harjola VP
Int J Cardiol; 2016 Jul; 215():26-31. PubMed ID: 27107540
[TBL] [Abstract][Full Text] [Related]
8. Assessment of sustained effects of levosimendan and dobutamine on left ventricular systolic functions by using novel tissue Doppler derived indices in patients with advanced heart failure.
Oner E; Erturk M; Birant A; Kurtar Mansıroglu A; Akturk IF; Karakurt H; Yalcin AA; Uzun F; Somuncu MU; Yildirim A
Cardiol J; 2015; 22(1):87-93. PubMed ID: 24846511
[TBL] [Abstract][Full Text] [Related]
9. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.
Adamopoulos S; Parissis JT; Iliodromitis EK; Paraskevaidis I; Tsiapras D; Farmakis D; Karatzas D; Gheorghiade M; Filippatos GS; Kremastinos DT
Am J Cardiol; 2006 Jul; 98(1):102-6. PubMed ID: 16784930
[TBL] [Abstract][Full Text] [Related]
10. Natriuretic peptide-guided levosimendan therapy for heart failure: a promising new approach.
Giamouzis G; Giannakoulas G; Tsarpalis K; Agha SA; Georgiopoulou V; Kalogeropoulos A; Karvounis H; Butler J
Int J Cardiol; 2008 Aug; 128(1):91-3; author reply 94-6. PubMed ID: 18495268
[No Abstract] [Full Text] [Related]
11. [The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].
Paksoy F; Ulaş T; Tursun I; Dal MS; Oztekin E; Borlu F
Anadolu Kardiyol Derg; 2012 Feb; 12(1):16-22. PubMed ID: 22214738
[TBL] [Abstract][Full Text] [Related]
12. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
[TBL] [Abstract][Full Text] [Related]
13. A struggle to SURVIVE: to abandon or not to abandon levosimendan?
Butler J; Giamouzis G; Giannakoulas G
Cardiovasc Drugs Ther; 2007 Oct; 21(5):401-2. PubMed ID: 17701453
[No Abstract] [Full Text] [Related]
14. Is levosimendan better than dobutamine in acute heart failure in patients on beta-blockade treatment? What is the evidence?
Omerovic E; Waagstein F; Swedberg K
Eur J Heart Fail; 2010 Apr; 12(4):313-4. PubMed ID: 20335348
[No Abstract] [Full Text] [Related]
15. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
Tek M; Cavuşoğlu Y; Demirüstü C; Birdane A; Ünalır A; Görenek B; Göktekin Ö; Ata N
Turk Kardiyol Dern Ars; 2010 Jul; 38(5):334-40. PubMed ID: 21200103
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure].
Wang L; Cui L; Wei JP; Li GP; Qi GX; Hao YM; Wang WZ; Li HM; Liu J; Jiang DJ; Zhang YD
Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Jun; 38(6):527-30. PubMed ID: 21033135
[TBL] [Abstract][Full Text] [Related]
17. How to treat acute decompensated heart failure in the 'beta-blocker era'?
Marcondes-Braga FG; Mangini S; Ayub-Ferreira SM; Bocchi EA; Bacal F
Eur J Heart Fail; 2010 Aug; 12(8):893-4. PubMed ID: 20675672
[No Abstract] [Full Text] [Related]
18. Cost-effectiveness of levosimendan in patients with acute heart failure.
Fedele F; D'Ambrosi A; Bruno N; Caira C; Brasolin B; Mancone M
J Cardiovasc Pharmacol; 2011 Oct; 58(4):363-6. PubMed ID: 21697728
[TBL] [Abstract][Full Text] [Related]
19. The use of levosimendan in comparison and in combination with dobutamine in the treatment of decompensated heart failure.
Cavusoglu Y
Expert Opin Pharmacother; 2007 Apr; 8(5):665-77. PubMed ID: 17376021
[TBL] [Abstract][Full Text] [Related]
20. The costs of treating acute heart failure: an economic analysis of the SURVIVE trial.
de Lissovoy G; Fraeman K; Salon J; Chay Woodward T; Sterz R
J Med Econ; 2008; 11(3):415-29. PubMed ID: 19450096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
